Risk factors of recurrent non-functioning pituitary adenomas in patients with growth hormone deficiency
Background. Nowadays, a search for diagnostically significant markers of aggressiveness of nonfunctioning pituitary adenomas remains relevant for further prognosis in the postoperative period. Nonfunctioning pituitary adenomas without pituitary hypersecretion are the forms of adenohypophysis tumors. In the general population, frequency of nonfunctioning pituitary adenomas is 50 cases per 1 million people. The purpose of the study is to determine the clinical diagnostic markers of tumor aggressiveness in patients with nonfunctioning pituitary adenomas and growth hormone deficiency, as well as their role in the severity of the neuroendocrine symptoms of the disease. Materials and methods. Under our supervision, there were 87 patients (44 men, 43 women), of them 31 with a verified diagnosis of nonfunctioning pituitary adenomas after transnasal hypophysectomy. Followup was from 1 to 3 years. Results. When patients were distributed in groups depending on histological description of nonfunctioning pituitary adenomas, those with chromophobe pituitary adenoma prevailed (77.5 %). Nonfunctioning pituitary adenomas in women were associated with obesity, primary and secondary hypothyroidism, secondary hypogonadism, syndrome of persistent galactorrheaamenorrhea (symptomatic and idiopathic forms), diabetes insipidus, empty sella syndrome and others. In men, nonfunctioning pituitary adenomas was accompanied by obesity, primary and secondary hypothyroidism, secondary hypogonadism, diabetes insipidus, gynecomastia. The scale developed to determine the markers of aggressiveness of nonfunctioning pituitary adenomas allowed identifying factors by 3 degrees and developing a set of measures to prevent the recurrence of tumor growth. Conclusions. Markers of aggressiveness of nonfunctioning pituitary adenomas are: young age of the patient, first symptoms of the disease, large tumor sizes, asymmetry and deformation of the pituitary gland, signs of tumor invasion into adjacent tissues/arteries/cavernous sinus, small cell and/or dark cell chromophobe adenomas, panhypopituitarism.
Full Text:PDF (Русский)
Katznelson L, Atkinson JL, Cook DM, et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly-2011 update. Endocr Pract. 2011 Jul-Aug;17 Suppl 4:1-44.
Cury ML, Fernandes JC, Machado HR, Elias LL, Moreira AC, Castro MD. Non-functioning pituitary adenomas: clinical feature, laboratorial and imaging assessment, therapeutic management and outcome. Arq Bras Endocrinol Metabol. 2009 Feb;53(1):31-9.
Mavromati M, Kuhn E, Agostini H, et al. Classification of Patients With GH Disorders May Vary According to the IGF-I Assay. J Clin Endocrinol Metab. 2017 Aug 1;102(8):2844-2852. doi: 10.1210/jc.2017-00202.
Daly AF, Rixhon M, Adam C, Dempegioti A, Tichomirowa MA, Beckers A. High prevalence of pituitary adenomas: a cross-sectionalstudy in the province of Liège, Belgium. J Clin Endocrinol Metab. 2006 Dec;91(12):4769-75. doi: 10.1210/jc.2006-1668.
Fernandez A, Karavitaki N, Wass JA. Prevalence of pituitary adenomas:a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin Endocrinol (Oxf). 2010 Mar;72(3):377-82. doi: 10.1111/j.1365-2265.2009.03667.x.
Cury ML, Fernandes JC, Machado HR, Elias LL, Moreira AC, Castro Md. Non-functioning pituitary adenomas: clinical feature, laboratorial and imaging assessment, therapeutic management and outcome. Arq Bras Endocrinol Metabol. 2009 Feb;53(1):31-9.
Khalimova ZYu, Kholova DS, Urmanova YuM, Alieva DA, Alimukhamedova GA, Nasirova KhK. Reproductive Function in Patients with Non-functioning Pituitary Adenoma According to the Register of the Republic of Uzbekistan. International Journal of Biomedicine. 2016;6(2):133-135 doi: 10.21103/Article6(2)_ShC1.
This work is licensed under a Creative Commons Attribution 4.0 International License.
© "Publishing House "Zaslavsky", 1997-2019